Covid19
Conditions
Keywords
LYMPHOCYTE MONOCYTE RATIO, COVID-19, DISEASE PROGRESSION
Brief summary
Corona virus disease 2019 (COVID 19), first identified in December 2019 in a cluster of population in a Chinese province, soon emerged as a pandemic, causing a huge strain on healthcare system and mortality all over the world. An ideal marker for predicting course of this illness should be easily available and reproducible; as the disease burden has spread to third world countries whose healthcare system is resource limited. Our study is aimed to study the utility of lymphocyte- monocyte ratio in the early stages to predict the progression of COVID 19 pneumonia.
Interventions
DIAGNOSTIC_TESTLYMPHOCYTE MONOCYTE RATIO
Absolute lymphicyte and absolute monocyte counts are recorded on admission of COVID -19 positive patient and ratio is derived. the patients are followed up for any progression of disease stage.
Sponsors
Sir Ganga Ram Hospital
Post Graduate Institute of Medical Education and Research, Chandigarh
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* All adults of age 18-80 years tested positive for SARS-CoV-2 reverse-transcriptase - polymerase chain reaction (rt-PCR) and presented within 7 days of symptom(s) onset
Exclusion criteria
* Pregnancy * Sepsis * Malignancy * Patients on immunosuppressant therapy * Chronic inflammatory conditions * Cases lost to follow up
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| progression | 28 days | disease progression equal or more than 2 stages |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| mortality | 28 days | end outcome of the patients diagnosed of COVID-19 infection |
Countries
India
Outcome results
None listed